Skip to main content
John Buse, MD

Results of the five-year GRADE trial, designed to understand the best second-line agent for patients with type 2 diabetes already taking metformin, were reported at the virtual American Diabetes Association (ADA) 81st Scientific Sessions and published in Medscape Medical News.

Researchers found the injectable drugs Lantus (glargine) and Victoza (liraglutide) outperformed the pills Amaryl (glimepiride) and Januvia (sitagliptin).

For the endpoint of any cardiovascular event, the rate was 5.8% for patients taking liraglutide, significantly less than the rate of 7.6% of those taking insulin glargine, 8.0% for glimepiride, and 8.6% for sitagliptin, reported John B. Buse, MD, PhD, professor of medicine in the division of endocrinology and metabolism.

Funded by the U.S. National Institutes of Health, the study included more than 5,000 people with type 2 diabetes and average age was 57.

Read the article.